首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2541篇
  免费   106篇
  国内免费   20篇
耳鼻咽喉   8篇
儿科学   43篇
妇产科学   221篇
基础医学   408篇
口腔科学   13篇
临床医学   156篇
内科学   309篇
皮肤病学   29篇
神经病学   106篇
特种医学   34篇
外科学   310篇
综合类   332篇
预防医学   171篇
眼科学   9篇
药学   200篇
  1篇
中国医学   92篇
肿瘤学   225篇
  2023年   28篇
  2022年   59篇
  2021年   74篇
  2020年   69篇
  2019年   51篇
  2018年   63篇
  2017年   67篇
  2016年   56篇
  2015年   76篇
  2014年   166篇
  2013年   199篇
  2012年   121篇
  2011年   159篇
  2010年   128篇
  2009年   132篇
  2008年   132篇
  2007年   148篇
  2006年   97篇
  2005年   117篇
  2004年   99篇
  2003年   64篇
  2002年   70篇
  2001年   66篇
  2000年   51篇
  1999年   40篇
  1998年   27篇
  1997年   25篇
  1996年   22篇
  1995年   40篇
  1994年   27篇
  1993年   14篇
  1992年   18篇
  1991年   17篇
  1990年   14篇
  1989年   9篇
  1988年   14篇
  1986年   7篇
  1985年   9篇
  1984年   12篇
  1983年   5篇
  1982年   5篇
  1981年   9篇
  1980年   6篇
  1979年   6篇
  1976年   4篇
  1974年   5篇
  1973年   6篇
  1972年   9篇
  1971年   4篇
  1970年   6篇
排序方式: 共有2667条查询结果,搜索用时 15 毫秒
1.
《Clinical breast cancer》2020,20(1):e89-e98
IntroductionA reliable risk stratification on the basis of tumor biology and host factors of HER2-positive (HER2+) early breast cancer (eBC) patients is needed. The aim of our study was to assess the prognostic role of body mass index (BMI) and hormone receptor (HR) expression in this setting.Patients and MethodsWe retrospectively evaluated 238 women with stage I to III HER2+ breast cancer who completed adjuvant chemotherapy (CHT) and 1 year of treatment with trastuzumab. The end point was 3-year distant disease-free survival (3yDDFS). Survival analysis was evaluated using the Kaplan–Meier method. Multivariate analysis was performed using Cox proportional-hazards model adjusting for HR status, BMI, tumor staging, size, nodal status, and type of adjuvant CHT. Association among categorical variables was assessed using χ2 test.ResultsThe early recurrence rate after 3 years resulted as 4.2% (40% HR+ patients and 60% HR patients). Neither HR status nor BMI alone showed an association with 3yDDFS in multivariate analysis. However, the hazard ratios for patients with HR tumors who had also BMI ≥25 (3yDDFS 86.9%; 95% confidence interval [CI], 75.0%-97.7%) were amplified compared with patients with HR+ tumors and with BMI <25 (3yDDFS 98%; 95% CI, 94.8%-100.0%) and other subgroups (P = .003). This observation was confirmed in multivariate analysis (hazard ratio, 1.79; 95% CI, 1.04-3.07; P = .03).ConclusionOur real-life data highlight a different risk of eBC recurrence after grouping patients according to HR status and BMI. These results might help clinicians to identify correct treatment strategies. Patients who are HR and have BMI ≥25 might benefit from escalation approaches, whereas those who are HR+ and have BMI <25 might be eligible for a shorter duration of adjuvant treatment with anti-HER2 agents.  相似文献   
2.
背景与目的:甲状旁腺切除术(PTX)是治疗药物不能控制的难治性肾性继发性甲状旁腺功能亢进症(SHPT)的重要手段,但PTX术后仍有可能发生永久性甲状旁腺功能减退,无动力性骨病或难治性骨软化症,且国内尚缺乏对PTX术后远期的疗效观察的研究。本研究进一步评价PTX治疗难治性肾性SHPT的安全性与近远期疗效。方法:纳入2011年1月—2014年12月在安徽医科大学第二附属医院行PTX治疗的139例伴有难治性肾性SHPT的维持性透析患者。收集患者术前及术后3 d、6个月及1、2、3年的临床资料、血全段甲状旁腺激素(iPTH)、血钙、血磷、血红蛋白(Hb)及红细胞压积(Hct)等,观察并记录术后症状缓解情况、术后并发症和随访情况。结果:139例患者的PTX手术成功率为95.7%(133/139),术中共计切除甲状旁腺腺体537枚,平均切除3.86枚/例。12例(8.6%)术后发生一过性喉返神经损伤,其中声音嘶哑9例(6.5%),饮水呛咳3例(2.2%),未予处理术后3个月内均自行好转。术后低钙血症或缺乏维生素D者120例(86.3%),给予西那卡塞、补钙及补充活性维生素D治疗后得到有效控制。全组未发生切口感染、出血、窒息及甲状腺功能减退等外科并发症。患者的贫血状况均有不同程度地改善,Hb和Hct术后6个月明显升高并在随访期间保持稳定;术后iPTH明显降低,术后3 d的血钙、磷、钙磷乘积水平最低,随访3年仍低于手术前,所有变化与术前均有统计学差异(均P0.05)。随访期间无死亡病例。患者术前的骨痛、顽固性皮肤瘙痒、失眠、异位钙化、肌无力伴萎缩症状在术后1 d即明显缓解;身高缩短、骨骼畸形患者随访期间无进行性加重;纳差、全身营养状况及自理能力术后3个月内不同程度地改善。11例(7.9%)持续性SHPT,包括4例(2.9%)术中未完全切除甲状旁腺腺体,1例(0.7%)术中1枚腺体较小而未切除完全,6例(4.3%)术后检查存在纵隔异位甲状旁腺。随访期间,5例(3.5%)腺体未切除完全者的iPTH均800 pg/mL,肌无力及顽固性皮肤瘙痒临床症状明显,再次行PTX;6例(4.3%)存在异位甲状旁腺腺体者,因手术风险较大患者拒绝再次手术,予以药物治疗;8例(5.8%)术后复发,其中6例(4.3%)系前臂移植物复发所致,均在局麻下行前臂皮下移植物切除;2例(1.4%)系颈部原位残留腺体过度增生,予以二次手术,术后症状缓解。所有进行二次手术的患者在随访结束时无明显的临床症状,均未复发。结论:PTX可改善难治性肾性SHPT患者临床症状、贫血及钙磷代谢,且近远期疗效均较好,是治疗难治性SHPT的安全有效方法。  相似文献   
3.
4.
5.
6.
BackgroundMenopausal symptoms have negative effects on the aspects of quality of life and impose a high cost on the health system. In traditional Persian medicine, pomegranate is recommended to alleviate menopausal symptoms.Material and methodsA randomized double-blind placebo-controlled trial was performed among 78 healthy women. Participants were interviewed three times: Before receiving the supplement/placebo, after completing the treatment, and after 3 weeks with no intervention. They filled out the demographic information sheet, modified-Kupperman index, and Menopause-Specific Quality of Life (MENQOL) questionnaires.ResultsThe mean scores of the modified-Kupperman index and MENQOL characteristics before and after the treatment and after the follow-up period were significantly different between pomegranate and placebo groups in both modified-Kupperman and MENQOL scores (p < 0.001).ConclusionThis study demonstrated that 4 weeks' treatment with the pomegranate supplement significantly ameliorates the irritating symptoms of menopause and improves the quality of life in menopausal women even after 4 weeks' medicine deprivation.  相似文献   
7.
BackgroundPrior reports demonstrate the expression of estrogen and progesterone receptors in high-grade gliomas (HGGs), but the relationship between hormone receptor-positive disease and risk of HHGs in patients with breast cancer (BC) remains uncharacterized.MethodsUsing the SEER 18 registries (2000–2017), we examined the temporal trend of the incidence of HGGs and BC. The standardized incidence ratio was calculated to assess the risk of subsequent HGG in BC patients.ResultsDuring the study period, the incidence of BC and HGGs remained comparable for men and women. Among 976,134 patients with BC, we found a decreased incidence of HGGs in females, but not in males. Female BC patients with hormone receptor-positive disease were at a lower risk of developing glioblastoma and anaplastic astrocytoma.ConclusionOur study findings allude to the protective role of hormone exposure in the development of HGGs, which may lead to the development of therapies targeting hormonal pathways.  相似文献   
8.
目的:探讨甲状旁腺鉴定(PGI)系统在甲状腺手术中快速鉴定甲状旁腺的临床价值。方法:收集2016年3月—2018年5月于江苏省原子医学研究所附属江原医院进行甲状腺手术的251例患者临床资料,所有患者术中用细针对可疑甲状旁腺组织进行穿刺,使用PGI系统通过检测穿刺组织液的甲状旁腺激素(PTH)浓度来鉴别是否为甲状旁腺,同时将穿刺的组织切少许送冷冻病理检查,以冷冻病理检测结果为对照标准,统计分析该鉴定系统鉴别甲状旁腺的准确性。结果:PGI系统共检测434份组织,其中无效检测16份,有效检测418份。在有效检测的组织中,PGI系统鉴定为甲状旁腺组织311份,非甲状旁腺组织组织107份;冷冻病理检查诊断为甲状旁腺组织314份,非甲状旁腺组织104份。两种检测方法有明显的一致性(к=0.969,P0.001)。使用PGI系统识别甲状旁腺的敏感度99.0%(309/312),特异度98.1%(104/106),阳性预测值99.4%(309/311),阴性预测值97.2%(104/107),误诊率1.9%(2/104),漏诊率1.0%(3/312),准确率98.8%(413/418)。所有患者术后均无出血或感染,均未出现永久性的甲状旁腺功能减退及喉返神经麻痹。结论:PGI系统可用于甲状腺手术中鉴别甲状旁腺组织,具有速度快、准确率高、操作简便、组织损伤小等特点。  相似文献   
9.

Introduction

In patients with high-risk localized prostate cancer (HRPCa), multimodal treatment plays a fundamental role.

Objective

To compare relapse-free survival (RFS) in patients with HRPCa, treated primarily with radiotherapy (RT) + hormone therapy (HT) versus radical prostatectomy (RP) and salvage RT (sRT) ± HT when biochemical recurrence (BCR) appears.

Material and methods

Retrospective analysis of 226 patients with HRPCa (1996-2008), treated primarily with RT + HT (n = 137) or RP (n = 89). The Kaplan-Meier method has been used to evaluate survival and the log-rank test has been used to evaluate the contrast between the different categories of the variables. Multivariate analysis has been performed using Cox regression to determine variables with an impact on RFS with statistical significance (P < 0.05).

Results

The median follow-up of the series was 111 (IQR 85-137.5) months. After RT + HT, 32 (23.4%) patients relapsed, and after RP (P = 0.0001), 41 (46.1%) cases. When comparing the primary treatments, the RFS at 5 and 10 years was higher after RT + HT versus RP in monotherapy (P = 0.001). The primary treatment with RT + HT reduced the risk of BCR when compared to the RP (HR = 0.41, P = 0.002). The estimation of the RFS at 5 and 10 years after RP + sRT ± HT was 89.7 and 87.1%, while after primary RT + HT was 91.6 and 71.1%, respectively (P = 0.01). The only factor that behaved as an independent predictor of RFS was the multimodal treatment with RP + sRT ± HT when BCR showed up (HR = 2.39, P = 0.01).

Conclusion

In HRPCa, multimodal treatment with RP + sRT ± HT if BCR, significantly improves RFS with respect to treatment with RT + HT.  相似文献   
10.
The incidence of breast cancer across the world has been on the rise in recent decades. Because identified risk factors can only explain a relatively small portion of the cases, environmental exposure to organic pollutants is suspected to play a role in breast cancer etiology. Polychlorinated biphenyls (PCBs) are among the most abundant pollutants, and the impact of their exposure on breast cancer risk has been extensively studied in recent decades. However, the results of most epidemiologic studies do not support an association between PCB exposure and breast cancer risk. We hypothesized that the effects of PCBs on breast cancer might have been undervalued for reasons such as insufficient recognition of the confounding effects of several factors and lack of attention on the innate heterogeneity of PCB mixtures or breast cancer. After reviewing the evidence in the existing literature, we concluded that early life exposure, known risk factors of breast cancer, and impact of exposure to other pollutants are the main sources of confounding effects and have potentially masked the associations between PCBs and breast cancer. Because PCBs are mixtures of congeners with varied properties, and because breast cancers of different subtypes are etiologically distinct diseases, the absence of stratified subgroup analysis on individual PCBs and patients with specific biological subtypes and insufficient attention paid to the results of these subgroup analyses may result in an underestimation of the correlations between PCBs and breast cancer. In future studies, these factors must be taken into consideration when exploring the effect of PCB exposure on breast cancer risk.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号